Servier Pharmaceuticals has received international recognition for its work in developing therapies for rare and complex diseases. The company focuses on targeted treatments that reflect ongoing advances in medical research.
Servier Pharmaceuticals: Pioneering Innovation in Oncology
Servier Pharmaceuticals is a global biopharmaceutical company engaged in the research and development of therapies for rare and complex diseases. In the field of oncology, the company focuses on identifying and developing targeted treatments for cancers that have limited treatment options or unmet medical needs. Its work spans multiple stages of drug development, from preclinical research to clinical trials, aiming to generate evidence on safety and efficacy and to expand therapeutic options for patients with challenging conditions.
Recognition in the Best Product for Rare/Orphan Diseases Category
In 2025, Servier Pharmaceuticals received the Prix Galien USA Award in the category of Best Product for Rare/Orphan Diseases. This recognition celebrates the development of Servier’s first targeted therapy for Grade 2 IDH-mutant glioma, a rare brain tumor. The award underscores the therapy’s transformative effect on patient care and its role in addressing an unmet need in oncology.
On its official social media channels, Servier expressed gratitude and pride
“Thank you to The Galien Foundation for this incredible honor. It’s a true privilege to be recognized for our work in developing the first targeted therapy for Grade 2 IDH-mutant glioma. This recognition is a testament to the life-changing impact of our glioma medicine – and a powerful reminder that no disease is too challenging to treat, and no patient population is too small to serve.”
Commitment to Patients with Rare Diseases
This accolade reflects Servier’s enduring commitment to ensuring that no disease is too challenging to treat and no patient population is too small to serve. By focusing on rare and orphan diseases, Servier continues to translate scientific innovation into therapies that make a real difference in patients’ lives.
Looking Ahead
The Prix Galien USA Award honors Servier’s achievements while inspiring ongoing dedication to research and development. As the company continues to expand its pipeline, it remains focused on delivering pioneering treatments to patients with rare and underserved conditions worldwide.
What Drives Science and What Guides Care? Redefining Glioma Treatment in 2025
Written by Nare Hovhannisyan, MD